Is Melanotan-1 Better Than MT-1? (Same Peptide Explained)

Here's what catches most researchers off guard: Melanotan-1 and MT-1 aren't two different peptides you're choosing between. They're identical compounds with the same 13-amino-acid sequence, the same mechanism of action, and the same melanocortin receptor binding profile. The naming difference exists because one term (Melanotan-1) describes the peptide's functional class and origin story, while the other (MT-1) serves as shorthand laboratory notation. No structural difference. No potency difference. No therapeutic distinction. The question 'which is better' assumes a comparison that doesn't exist.

Our team has reviewed thousands of peptide specifications across research contexts. The pattern is consistent: when researchers ask whether Melanotan-1 is better than MT-1, they're operating under the assumption that naming variation signals molecular variation. It doesn't. What matters is purity, synthesis method, storage protocol, and dosing precision. The label on the vial is secondary.

Is Melanotan-1 better than MT-1?

Melanotan-1 and MT-1 are the same peptide. A synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) consisting of 13 amino acids. The naming difference reflects convention, not chemistry. Both terms refer to the identical molecular structure (Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) with the same melanocortin-1 receptor (MC1R) binding affinity. Choosing between them is like asking whether H2O is better than water. The substance is identical regardless of nomenclature.

The real confusion stems from how peptides get named during research phases. Melanotan-1 was the original designation given during early development at the University of Arizona in the 1980s, when researchers were synthesising α-MSH analogues to investigate melanogenesis and photoprotection. MT-1 emerged as laboratory shorthand once the compound entered broader preclinical and clinical investigation. Both names persisted across different research institutions, publications, and eventually commercial suppliers. Creating the false impression of distinct compounds.

Here's the honest answer: if you're comparing product listings or supplier catalogues that list both 'Melanotan-1' and 'MT-1' as separate options, you're not looking at two peptides. You're looking at naming inconsistency within the same supplier or across different vendors. The functional question isn't which name is better; it's which supplier provides the peptide at the purity, lyophilisation standard, and storage condition your research protocol requires. This article covers the molecular identity both names share, why the naming divergence happened, what structural features define the peptide regardless of label, and what actually matters when selecting a research-grade melanocortin agonist.

Why the Same Peptide Has Two Names

The naming split traces back to peptide nomenclature conventions used during early synthetic analogue development. When the University of Arizona research team. Led by Dr Victor Hruby and Dr Mac Hadley. Began synthesising shortened α-MSH analogues in the mid-1980s, they needed a way to distinguish their experimental compounds from native α-MSH (a 13-amino-acid hormone) and from other melanocortin peptides under investigation elsewhere. They designated their lead candidate 'Melanotan'. Combining 'melano' (pigment) with 'tan' (the desired tanning effect). And numbered it Melanotan-1 to differentiate it from a second-generation cyclic analogue (Melanotan-2) they developed later with a different receptor profile.

MT-1 emerged as shorthand notation when the peptide entered formal preclinical studies and regulatory filings. Research publications, particularly those outside the originating lab, adopted 'MT-1' for brevity. The same way somatostatin analogues get abbreviated (e.g., octreotide as OCT). By the time Melanotan-1 entered Phase I and Phase II clinical trials in Australia and Europe during the 1990s, both names were circulating in parallel across scientific literature, clinical trial registries, and eventually peptide supply chains. The dual nomenclature stuck because no single regulatory body or naming authority forced consolidation. Unlike drug trade names, which are tightly controlled post-approval.

Our experience working with peptide research protocols confirms this pattern: peptides developed in academic settings often carry informal lab names that persist even after entering commercial synthesis. The α-MSH analogue known as Melanotan-1 or MT-1 isn't unique in this. GHRP-6, hexarelin, and ipamorelin all have multiple names depending on whether you're reading a patent filing, a clinical trial summary, or a supplier product sheet. The key insight: naming variation doesn't predict molecular variation. What predicts quality is synthesis method, purity assay, and handling protocol. Not whether the label says Melanotan-1 or MT-1.

The Molecular Structure Both Names Share

Regardless of which name appears on documentation, the peptide in question is a linear 13-amino-acid sequence: Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. This sequence is a synthetic analogue of endogenous α-MSH but includes two critical structural modifications that distinguish it from the native hormone: substitution of methionine at position 4 with norleucine (Nle), and incorporation of D-phenylalanine (D-Phe) at position 7 instead of the naturally occurring L-phenylalanine. These modifications extend the peptide's half-life by resisting enzymatic degradation. Native α-MSH is rapidly cleaved by serum proteases within minutes, while Melanotan-1 (MT-1) maintains bioactivity for hours.

The norleucine substitution prevents oxidative degradation at the methionine site, which in native α-MSH is a known vulnerability under physiological conditions. The D-amino acid substitution at position 7 introduces chirality that blocks proteolytic cleavage by endopeptidases that recognise L-amino acid sequences. Together, these changes make the peptide significantly more stable without altering its ability to bind melanocortin-1 receptors (MC1R). The G-protein-coupled receptors expressed on melanocytes that mediate melanogenesis and pigmentation.

MC1R binding affinity is identical whether the vial label says Melanotan-1 or MT-1, because the receptor recognises the core His-D-Phe-Arg-Trp tetrapeptide motif (positions 6–9). The same sequence present in native α-MSH and conserved across both synthetic analogues. This motif is the 'message' sequence responsible for receptor activation. The flanking amino acids (positions 1–5 and 10–13) modulate binding kinetics and resistance to degradation but don't change the fundamental melanocortin receptor interaction. Research published in the Journal of Medicinal Chemistry during initial analogue characterisation confirmed that Melanotan-1 exhibits MC1R selectivity with minimal cross-reactivity to MC3R, MC4R, or MC5R. The other melanocortin receptor subtypes involved in appetite regulation, energy expenditure, and exocrine function.

Melanotan-1 vs MT-1: Functional Comparison

Key Takeaways

• Melanotan-1 and MT-1 refer to the same 13-amino-acid synthetic α-MSH analogue with identical molecular structure, receptor binding, and melanogenic mechanism.
• The naming divergence originated during peptide development. Melanotan-1 from the originating University of Arizona lab, MT-1 as shorthand notation in broader research literature.
• Both names describe a peptide with norleucine at position 4 and D-phenylalanine at position 7, modifications that extend half-life by resisting proteolytic degradation.
• MC1R binding affinity and selectivity are identical regardless of nomenclature. The core His-D-Phe-Arg-Trp sequence drives melanocortin receptor activation.
• Quality depends on synthesis purity, lyophilisation protocol, and storage conditions. Not on which name appears on the supplier label.
• Suppliers listing both 'Melanotan-1' and 'MT-1' as distinct products are using inconsistent naming, not offering two different compounds.

What If: Melanotan-1 and MT-1 Scenarios

What If a Supplier Lists Both Melanotan-1 and MT-1 at Different Prices?

Contact the supplier directly to confirm whether the products represent the same peptide with identical purity and synthesis batch. If they confirm both listings refer to the same compound, the price difference likely reflects packaging size, volume discount, or inventory management rather than molecular distinction. If the supplier claims the products differ, request COA (certificate of analysis) documentation showing HPLC purity, mass spectrometry, and amino acid sequencing for both. Genuine structural differences would be reflected in these assays. Our experience suggests most dual-listing cases are cataloguing errors rather than intentional differentiation.

What If Research Protocols Specify 'Melanotan-1' But the Available Product Is Labeled 'MT-1'?

Verify the amino acid sequence matches the 13-residue structure (Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) using the supplier's COA or product specification sheet. If the sequence is identical and purity meets protocol requirements (typically ≥98% by HPLC for research-grade peptides), the naming difference is irrelevant to experimental validity. Document the peptide's actual molecular identity in your methods section rather than relying solely on the commercial name. This practice applies to all synthetic peptides, not just melanocortin analogues.

What If You're Comparing Melanotan-1 to Melanotan-2 Instead?

Melanotan-2 (MT-2) is a structurally distinct cyclic peptide with broader melanocortin receptor activity. It binds MC1R, MC3R, and MC4R, producing melanogenesis alongside appetite suppression and other central effects. The molecular difference is significant: Melanotan-2 contains only 7 amino acids in a cyclic configuration (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2), while Melanotan-1 remains a linear 13-amino-acid peptide. They're not interchangeable. If your research goal involves selective MC1R activation without MC3R/MC4R cross-reactivity, Melanotan-1 (or MT-1, same peptide) is the appropriate choice. If you need multi-receptor melanocortin activity, Melanotan-2 is mechanistically different.

The Blunt Truth About Peptide Naming Confusion

Here's the honest answer: peptide nomenclature is inconsistent across suppliers, and dual naming for the same compound is common. Melanotan-1 and MT-1 are identical, but you'll encounter the same naming redundancy with other research peptides. GHRP-6 is sometimes listed as Growth Hormone Releasing Peptide-6, hexarelin appears as Examorelin, and BPC-157 has at least three naming variants depending on whether the supplier uses the sequence notation, the functional descriptor, or the laboratory shorthand. The pattern extends across dozens of synthetic peptides.

The practical implication: don't rely on product names alone when selecting peptides. Verify molecular identity using sequence data, request certificates of analysis showing HPLC purity and mass spectrometry confirmation, and cross-check the amino acid sequence against published literature for the peptide you intend to use. Naming inconsistency isn't a red flag for supplier quality. It's a persistent feature of peptide commerce that researchers navigate by validating molecular identity rather than trusting labels.

For teams working with melanocortin receptor research, the naming question becomes irrelevant once you confirm the sequence. Whether your supplier calls it Melanotan-1, MT-1, or even α-MSH analogue (13aa), what matters is that the peptide contains norleucine at position 4, D-phenylalanine at position 7, and demonstrates MC1R selectivity without significant MC3R or MC4R binding. Those are the functional parameters that define the compound. Not the name printed on the vial.

What Actually Differentiates Research-Grade Melanocortin Peptides

If Melanotan-1 and MT-1 are functionally identical, what should researchers evaluate when comparing supplier offerings? Three factors dominate: synthesis purity, lyophilisation quality, and post-reconstitution stability. HPLC purity above 98% is the baseline standard for research-grade peptides. Lower purity introduces sequence truncations, deletion peptides, and synthesis by-products that can confound experimental results. Mass spectrometry confirmation ensures the peptide's molecular weight matches the expected value (1646.9 Da for Melanotan-1/MT-1), ruling out incorrect synthesis or sequence errors.

Lyophilisation quality affects reconstitution behaviour and long-term storage stability. Poorly lyophilised peptides form clumps that dissolve incompletely, creating concentration inconsistencies across aliquots. High-quality lyophilisation produces a uniform powder that reconstitutes rapidly in bacteriostatic water without visible aggregation. Storage at −20°C maintains peptide integrity for 12–24 months when lyophilised; once reconstituted, refrigeration at 2–8°C and use within 28 days prevents hydrolytic degradation and oxidation.

Post-reconstitution stability testing. Typically conducted via HPLC at multiple timepoints after mixing. Reveals how quickly the peptide degrades under storage conditions. Melanotan-1 (MT-1) remains stable in bacteriostatic water at 4°C for approximately 4 weeks, but degradation accelerates significantly if stored at room temperature or exposed to repeated freeze-thaw cycles. Suppliers providing stability data demonstrate quality control beyond basic purity testing. Our team has found that peptides meeting these three criteria. High HPLC purity, proper lyophilisation, and documented post-reconstitution stability. Perform consistently across research applications regardless of whether the label says Melanotan-1 or MT-1.

For researchers requiring melanocortin receptor tools, Real Peptides supplies research-grade peptides synthesised through small-batch solid-phase synthesis with exact amino-acid sequencing, providing the purity and consistency required for reproducible melanogenesis studies. The commitment to precision synthesis ensures that peptide identity matches specification. Whether your protocol references Melanotan-1, MT-1, or any other nomenclature variant.

The naming confusion around Melanotan-1 versus MT-1 highlights a broader challenge in peptide research: commercial nomenclature doesn't always align with molecular reality. The peptides are identical. The sequence is identical. The mechanism is identical. What differs is supplier quality control, synthesis precision, and storage integrity. If you're selecting a melanocortin agonist for research, verify the molecular structure, confirm the purity, and document the sequence in your methods. The name on the vial is secondary to the compound inside it.